Sydney M Crago

At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology

At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

Ahead of the meeting, several companies previewed product pipeline announcements and research data presentations

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

The approval marks the first new steroid on the US ophthalmic market in more than 15 years

Sydney M Crago, editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial, presented at the 2024 Angiogenesis Symposium

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Catch up on Modern Retina's top stories, and ones you may have missed in 2023

EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema

The study results will help to identify dosing levels for future clinical trials

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

In a study presented at the American Academy of Ophthalmology meeting, researchers asked practicing ophthalmologists to compare the ability of ChatGPT, Google Bard and Bing Chat in answering common patient questions

Researchers at the University of Western Australia examined declining vision and increased risk of car accidents

Several companies including Kiora Pharmaceuticals, Adverum Biotechnologies and Aviceda Therapeutics, will share data at the 2023 meeting in San Francisco, California

Data indicated switching to SB15 from AFL maintained comparable clinical efficacy and safety, confirming biosimilarity between these agents

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD"

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.